Statement on FDA’s Proposed Oversight of Laboratory-Developed Tests

Posted on by admin

A statement on the announcement by the Food and Drug Administration (FDA) that it plans to take steps to improve the oversight of laboratory-developed tests (LDTs).
SOURCE: NIH Director’s Page – Read entire story here.

Related posts:

  1. NIH featured on C-SPAN’s Washington Journal Watch NIH leadership on C-SPAN's Washington Journal discussing important, groundbreaking research for multiple diseases and conditions. ...
  2. Phaedra Corso named UGA Foundation Professor of Human Health Phaedra Corso, Ph.D., MPA, professor of health policy and management in the University of Georgia College of Public Health, has been named the inaugural UGA Foundation Professor of Human Health.  The professorship was approved by the Board of Regents at its September 2013 meeting and became effective Jan. 1. read more ...
  3. Comparative Effectiveness And Cost-Effectiveness Analyses Frequently Agree On Value [Value & Quality] The Patient-Centered Outcomes Research Institute, known as PCORI, was established by Congress as part of the Affordable Care Act (ACA) to promote evidence-based treatment. Provisions of the ACA prohibit the use of a cost-effectiveness analysis threshold and quality-adjusted life-years (QALYs) in PCORI comparative effectiveness studies, which has been understood as a prohibition on support for PCORI’s conducting conventional cost-effectiveness analyses. This constraint complicates evidence-based choices where incremental improvements in outcomes are achieved at increased costs of care. How frequently this limitation inhibits efficient cost containment, also a goal of the ACA, depends on how often more effective treatment is not...
  4. Fixing problems with cell lines Dr. Collins and NIGMS Director Dr. Jon Lorsch author an article in Science Magazine addressing cell line misidentification in research and suggesting best practices for authentication and verification. Science Magazine. December 19, 2014. ...
  5. Appointment of Adrienne A. Hallett as the Associate Director for Legislative Policy and Analysis, NIH Ms. Hallett will join NIH on May 4, 2015. ...

Related Posts

Draft recommendations on screening mammography continue to stir debate

The release of new guidelines on mammography never fails to renew the heated controversy over the potential benefits and harms of this procedure. The latest draft guidelines from the U.S. Preventive Services Task Force (USPSTF) are no exception. Various expert bodies have already taken conflicting positions on them. You can have your say, too, if you hurry — public comment on the draft closes today. Screening mammography is done in healthy women to spot hidden breast cancer. Some expert groups say that women should begin having regular mammograms at age 40, others set the start age at 50. The age at which women should stop having mammograms is also disputed. The USPSTF is an independent panel of experts in primary care and prevention. It is charged with making

Feeling Grey About Fifty Shades

The following post originally ran on Huffington Post Women on April 16th and can be seen here. The author is Aimee Gallagher, MPH, MS the Scientific Program Manager at the Society for Women’s Health Research. The much-anticipated release of the Fifty Shades of Grey movie and its novel series precursor struck chords of concern among women’s health advocates. While the book sold over 100 million copies worldwide and has been heralded as an erotic romance novel that is sexually liberating, the nature of the protagonists’ relationship is troubling because of its multiple aspects of domestic violence. Domestic violence affects approximately one in three women [1]. Stalking, manipulation, intimidation, and rape all are forms of domestic violence and abuse. Anastasia Steele, the lead character in